Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, Srikanth Deenadayalan, Andrea Navarria, Mette Gislum, Nobuya Inagaki, T. Arisaka, T. Asakura, N. Azuma, S. Fukuda, Y. Fukushima, N. Harada, S. Inoue, H. Ishida, H. Ishii, S. Ishikawa, H. Jinnouchi, S. Kaneko, K. KannoM. Kato, Y. Kato, T. Kawada, H. Kim, A. Kiyosue, O. Matsuoka, O. Miho, S. Nakamoto, S. Nakamura, S. Nakanishi, H. Nishimura, A. Numata, T. Ohama, T. Okabe, F. Okuguchi, T. Osonoi, T. Sasaki, H. Seino, K. Shin, T. Shiraiwa, T. Sugiura, S. Wada, A. Yamauchi

Research output: Contribution to journalArticlepeer-review

52 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial'. Together they form a unique fingerprint.

Medicine & Life Sciences